Reading through circular RNAs in MASLD: new diagnostic and therapeutic opportunities may come around [0.03%]
MASLD中 Circular RNA的阅读：新的诊断和治疗机会可能会出现
Maite G Fernandez-Barrena,Matias A Avila
Maite G Fernandez-Barrena
Vlad Ratziu,Frank Tacke
Vlad Ratziu
Zonal control of liver inflammation is orchestrated by periportal kupffer cells [0.03%]
中心静脉区库普弗细胞调控肝炎炎症反应
Prakash Ramachandran
Prakash Ramachandran
Vlad Ratziu
Vlad Ratziu
From the Editor's Desk. [0.03%]
编者的絮语
Philip Newsome,Frank Tacke,Heiner Wedemeyer et al.
Philip Newsome et al.
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD [0.03%]
泛PPAR激动剂lanifibranor可改善T2D合并MASLD患者的胰岛素抵抗和肝脂肪变性
Diana Barb,Srilaxmi Kalavalapalli,Eddison Godinez Leiva et al.
Diana Barb et al.
Background & aims: Lanifibranor is a pan-PPAR agonist that improves glucose/lipid metabolism and reverses steatohepatitis and fibrosis in adults with MASH. We tested its effect on insulin resistance at the level of differ...
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial [0.03%]
肝硬化患者肠内微生物群移植治疗肝性脑病：THEMATIC试验
Jasmohan S Bajaj,Andrew Fagan,Edith A Gavis et al.
Jasmohan S Bajaj et al.
Background: Preventing hepatic encephalopathy (HE) recurrence in cirrhosis, which is associated with an altered gut-liver-brain axis, is an unmet need. Fecal microbiota transplantation (FMT) is beneficial in phase-1 studi...